Patents by Inventor Mark Tawa

Mark Tawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Co-crystal of etravirine and nicotinamide
    Patent number: 8754093
    Abstract: Etravirine (TMC125) nicotinamide co-crystal, its preparation, and use in the treatment of HIV infection.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: June 17, 2014
    Assignee: Janssen R&D Ireland
    Inventors: Matthew F. Sansone, Mark Tawa, Julius F. Remenar, Lieven Elvire Colette Baert
  • Pharmaceutical propylene glycol solvate compositions
    Patent number: 8492423
    Abstract: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: July 23, 2013
    Assignee: McNeil-PPC, Inc.
    Inventors: Mark Tawa, Örn Almarsson, Julius Remenar
  • Pharmaceutical forms, and methods of making and using the same
    Patent number: 8436029
    Abstract: Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.
    Type: Grant
    Filed: March 17, 2005
    Date of Patent: May 7, 2013
    Assignees: Transform Pharmaceuticals, Inc., University of South Florida
    Inventors: Magali Bourghol Hickey, Matthew L. Peterson, Örn Almarsson, Michael J. Zaworotko, Tanise Shattock, Julius F. Remenar, Mark Tawa
  • Pharmaceutical compositions with improved dissolution
    Patent number: 8362062
    Abstract: The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: January 29, 2013
    Assignee: McNeil-PPC, Inc.
    Inventors: Mark Tawa, Julius Remenar, Matthew L. Peterson, Örn Almarsson, Hector Guzman, Hongming Chen, Mark Oliveira
  • PHARMACEUTICAL PROPYLENE GLYCOL SOLVATE COMPOSITIONS
    Publication number: 20120190662
    Abstract: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.
    Type: Application
    Filed: April 3, 2012
    Publication date: July 26, 2012
    Inventors: Mark Tawa, Örn Almarsson, Julius Remenar
  • Tianeptine sulfate salt forms and methods of making and using the same
    Patent number: 8198268
    Abstract: Disclosed herein is a novel sulfate salt of tianeptine with improved properties. Also described herein are novel pharmaceutical compositions comprising tianeptine sulfate salt, methods of making, and related methods of treatment.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: June 12, 2012
    Assignee: Janssen Biotech, Inc.
    Inventors: Hector Guzman, Alexey Popov, Thomas J. L. Rammeloo, Julius Remenar, Jihad B. Saoud, Mark Tawa
  • Pharmaceutically acceptable propylene glycol solvate of naproxen
    Patent number: 8183290
    Abstract: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs. In particular a 2:1 complex of naproxen sodium to propylene glycol is disclosed which is a crystalline solid. The complex is prepared by crystallization of a mixture of naproxen sodium and propylene glycol from diethyl ether. It is identifiable by its X-ray powder diffraction pattern described herein.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: May 22, 2012
    Assignee: McNeil-PPC, Inc.
    Inventors: Mark Tawa, Örn Almarsson, Julius Remenar
  • CO-CRYSTAL OF ETRAVIRINE AND NICOTINAMIDE
    Publication number: 20120028998
    Abstract: Etravirine (TMC125) nicotinamide co-crystal, its preparation, and use in the treatment of HIV infection.
    Type: Application
    Filed: March 26, 2010
    Publication date: February 2, 2012
    Inventors: Matthew F. Sansone, Lieven Elvire Colette Baert, Mark Tawa, Julius F. Remenar
  • Novel Pharmaceutical Forms, and Methods of Making and Using the Same
    Publication number: 20120015993
    Abstract: Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.
    Type: Application
    Filed: March 17, 2005
    Publication date: January 19, 2012
    Applicants: University of South Florida, TRANSFORM PHARMACEUTICALS, INC.
    Inventors: Magali Bourghol Hickey, Matthew L. Peterson, Örn Almarsson, Michael J. Zaworotko, Tanise Shattock, Jennifer McMahon, Joanna Bis, Julius F. Remenar, Mark Tawa
  • Pharmaceutical Propylene Glycol Solvate Compositions
    Publication number: 20100279993
    Abstract: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.
    Type: Application
    Filed: July 20, 2010
    Publication date: November 4, 2010
    Inventors: Mark Tawa, Örn Almarsson, Julius Remenar
  • Pharmaceutical propylene glycol solvate compositions
    Patent number: 7790905
    Abstract: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: September 7, 2010
    Assignee: McNeil-PPC, Inc.
    Inventors: Mark Tawa, Örn Almarsson, Julius Remenar
  • TIANEPTINE SULFATE SALT FORMS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20100112051
    Abstract: Disclosed herein is a novel sulfate salt of tianeptine with improved properties. Also described herein are novel pharmaceutical compositions comprising tianeptine sulfate salt, methods of making, and related methods of treatment.
    Type: Application
    Filed: October 23, 2009
    Publication date: May 6, 2010
    Inventors: Hector Guzman, Alexey Popov, Thomas J.L. Rammeloo, Julius Remenar, Jihad B. Saoud, Mark Tawa
  • Sertraline compositions
    Patent number: 7186863
    Abstract: An acid salt of sertraline, wherein the acid is citric acid, fumaric acid, malic acid, maleic acid, malonic acid, phosphoric acid, succinic acid, sulfuric acid, L-tartaric acid, HBr, acetic acid, benzoic acid, benzenesulfonic acid, ethanesulfonic acid, lactic acid, methanesulfonic acid or toluenesulfonic acid. Similarly, a solvate of sertraline HCl, wherein the solvent is methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, acetic acid, ethyl acetate, or propylene glycol.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: March 6, 2007
    Assignee: TransForm Pharmaceuticals, Inc.
    Inventors: Julius Remenar, Michael MacPhee, Matthew Lynn Peterson, Mark Tawa
  • Pharmaceutical propylene glycol solvate compositions
    Publication number: 20070015841
    Abstract: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.
    Type: Application
    Filed: December 29, 2003
    Publication date: January 18, 2007
    Applicant: TransForm Pharmaceuticals, Inc.
    Inventors: Mark Tawa, Orn Almarsson, Julius Remenar
  • Novel Crystalline Forms of Tiotropium Bromide
    Publication number: 20060246009
    Abstract: The invention relates to new crystalline forms of tiotropium bromide, processes for preparing them and their use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
    Type: Application
    Filed: May 1, 2006
    Publication date: November 2, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Sherry Morissette, Mark Tawa, Mark Oliveira
  • Pharmaceutical compositions with improved dissolution
    Publication number: 20060134198
    Abstract: The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.
    Type: Application
    Filed: December 24, 2003
    Publication date: June 22, 2006
    Inventors: Mark Tawa, Julius Remenar, Matthew Peterson, Orn Almarsson, Hector Guzman, Hongming Chen, Mark Oliveira
  • Pharmaceutical compositions with improved dissolution
    Publication number: 20060052432
    Abstract: The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.
    Type: Application
    Filed: September 16, 2003
    Publication date: March 9, 2006
    Inventors: Julius Remenar, Matthew Peterson, Orn Almarsson, Hector Guzman, Hongming Chen, Mark Tawa, Mark Oliveira
  • Pharmaceutical salts of zafirlukast
    Publication number: 20050113410
    Abstract: Zafirlukast, a leukotriene receptor antagonist, converts to a less bioavailable form in the presence of water. The present invention relates to crystalline forms of zafirlukast including salts and solvates of zafirlukast substantially more stable in water than presently marketed zafirlukast. A method of preparing the compounds of the present invention is disclosed, as well as a method of treating asthma.
    Type: Application
    Filed: October 28, 2004
    Publication date: May 26, 2005
    Inventors: Mark Tawa, Orn Almarsson, Julius Remenar
  • Pharmaceutical compositions with improved dissolution
    Publication number: 20050025791
    Abstract: The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a recrystallization/precipitation retardant and an optional enhancer.
    Type: Application
    Filed: June 20, 2003
    Publication date: February 3, 2005
    Inventors: Julius Remenar, Matthew Peterson, Orn Almarsson, Hector Guzman, Hongming Chen, Mark Tawa, Mark Oliveira
  • Sertraline compositions
    Publication number: 20050014829
    Abstract: An acid salt of sertraline, wherein the acid is citric acid, fumaric acid, malic acid, maleic acid, malonic acid, phosphoric acid, succinic acid, sulfuric acid, L-tartaric acid, HBr, acetic acid, benzoic acid, benzenesulfonic acid, ethanesulfonic acid, lactic acid, methanesulfonic acid or toluenesulfonic acid. Similarly, a solvate of sertraline HCl, wherein the solvent is methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, acetic acid, ethyl acetate, or propylene glycol.
    Type: Application
    Filed: May 21, 2004
    Publication date: January 20, 2005
    Inventors: Julius Remenar, Michael MacPhee, Matthew Peterson, Mark Tawa